WO1994014434A1 - Endothelin receptor antagonists - Google Patents

Endothelin receptor antagonists Download PDF

Info

Publication number
WO1994014434A1
WO1994014434A1 PCT/US1993/012435 US9312435W WO9414434A1 WO 1994014434 A1 WO1994014434 A1 WO 1994014434A1 US 9312435 W US9312435 W US 9312435W WO 9414434 A1 WO9414434 A1 WO 9414434A1
Authority
WO
WIPO (PCT)
Prior art keywords
indole
alkyl
carboxylic acid
compound
hydrogen
Prior art date
Application number
PCT/US1993/012435
Other languages
French (fr)
Inventor
John Duncan Elliott
Jack Dale Leber
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to AU58735/94A priority Critical patent/AU5873594A/en
Priority to JP6515386A priority patent/JPH08504826A/en
Priority to US08/464,613 priority patent/US5686481A/en
Priority to EP94904877A priority patent/EP0676959A4/en
Publication of WO1994014434A1 publication Critical patent/WO1994014434A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel indole derivatives, pharmaceutical compositions containing these compounds and their use as endothelin receptor
  • Endothelin is a highly potent
  • vasoconstrictor peptide synthesized and released by the vascular endothelium exists as three
  • endothelin shall mean any or all of the isoforms of endothelin].
  • Endothelin has profound effects on the cardiovascular system, and in particular, the coronary, renal and cerebral circulation. Elevated or abnormal release of endothelin is associated with smooth muscle contraction which is involved in the pathogenesis of cardiovascular, cerebrovascular, respiratory and renal pathophysiology. Elevated levels of endothelin have been reported in plasma from patients with essential
  • endothelin has pronounced effects on blood pressure and cardiac output.
  • An intravenous bolus injection of ET (0.1 to 3 nmol/kg) in rats causes a transient, dose-related depressor response (lasting 0.5 to 2 minutes) followed by a sustained, dose-dependent rise in arterial blood pressure which can remain elevated for 2 to 3 hours following dosing. Doses above 3 nmol/kg in a rat often prove fatal.
  • Endothelin appears to produce a preferential effect in the renal vascular bed. It produces a marked, long-lasting decrease in renal blood flow, accompanied by a significant decrease in GFR, urine volume, urinary sodium and potassium excretion. Endothelin produces a sustained antinatriuretic effect, despite significant elevations in atrial natriuretic peptide. Endothelin also stimulates plasma renin activity.
  • ET may be an important mediator of cerebral vasospasm, a frequent and often fatal consequence of subarachnoid hemorrhage.
  • ET also exhibits direct central nervous system effects such as severe apnea and ischemic lesions which suggests that ET may contribute to the development of cerebral infarcts and neuronal death.
  • ET has also been implicated in myocardial ischemia (Nichols et al. Br. J. Pharm. 99: 597-601, 1989 and Clozel and Clozel, Cire. Res., 65: 1193-1200, 1989) coronary vasospasm (Fukuda et al., Eur. J. Pharm. 165: 301-304, 1989 and L ⁇ scher, Circ. 83: 701, 1991) heart failure, proliferation of vascular smooth muscle cells, (Takagi, B-iochem & Biophys . Res. Commun.; 168: 537-543, 1990, Bobek et al ., Am. J. Physiol.
  • endothelin has been found to be a potent constrictor of isolated mammalian airway tissue including human bronchus (Uchida et al., Eur J. of Pharm. 154: 227-228 1988, LaGente, Clin. Exp. Allergy 20: 343- 348, 1990; and Springall et al ., Lancet, 337: 697-701,
  • Kidney Int, 37: 1487-1491, 1990 and endotoxin shock and other endotoxin induced diseases (Biochem, Biophys, Res. Commun., 161: 1220-1227, 1989, Acta Physiol. Scand. 137: 317-318, 1989).
  • endothelin receptor antagonists would offer a unique approach toward the pharmacotherapy of hypertension, renal failure, cerebrovascular disease, myocardial ischemia, angina, heart failure, asthma, atherosclerosis, Raynaud's phenomenon, ulcers, sepsis, migraine, glaucoma, endotoxin shock, endotoxin induced multiple organ failure or disseminated intravascular coagulation, cyclosporin-induced renal failure and as an adjunct in angioplasty and prevention of restenosis.
  • This invention comprises indole derivatives represented by Formula (I) and pharmaceutical
  • compositions containing these compounds, and their use as endothelin receptor antagonists which are useful in the treatment of a variety of cardiovascular and renal diseases including but not limited to: hypertension, acute and chronic renal failure, cyclosporine induced nephrotoxicity, stroke, cerebrovascular vasospasm, myocardial ischemia, angina, heart failure and
  • This invention further constitutes a method for antagonizing endothelin receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I).
  • R 1 is -X(CH 2 ) n Ar or -X(CH 2 ) n R 8 or
  • R 2 is hydrogen, Ar or (c) ;
  • P 1 is -X (CH 2 ) n R 8 ;
  • P 2 is -X (CH 2 ) n R 8 , or -XR 9 Y;
  • R 3 and R 5 are independently hydrogen, R 11 , OH, C 1-8 alkoxy, S(O) q R 11 , N(R 6 ) 2 , Br, F, I, Cl, CF 3 , NHCOR 6 , -R 11 CO 2 R 7 , -XR 9 -Y, XY or -X(CH 2 ) n R 8 wherein the methylene groups of -X(CH 2 ) n R 8 may be unsubstituted or substituted by one or more -(CH 2 ) n Ar groups;
  • R 4 is hydrogen, Ar, R 11 , OH, C 1-5 alkoxy,
  • R 6 is independently hydrogen or C 1-4 alkyl
  • R 7 is independently hydrogen, C 1-6 alkyl or (CH 2 ) n Ar;
  • R 8 is hydrogen, R 11 , CO 2 R7, CO 2 C(R7) 2 O(CO)XR 7 , -N(R 7 )SO 2 R 7 , PO 3 (R 7 ) 2 ; SO 2 NR 7 R 11 , CONR 7 SO 2 R 11 ,
  • R 9 is C 1-10 alkyl, C 2-10 alkenyl or phenyl all of which may be unsubstituted or substituted by one or more OH, N(R 6 ) 2 , COOH, halogen or XC 1- 5 alkyl;
  • R 10 is R 3 or R 4 ;
  • R 11 is C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl all of which may be unsubstituted or substituted by one or more OH, CH 2 OH, N(R 6 ) 2 or halogen;
  • X is (CH 2 ) n , O, NR 6 or S(O) q ;
  • Y is CH 3 or -X(CH 2 ) n Ar
  • Ar is:
  • B is -CH 2 - or -O-;
  • q is zero, one or two
  • n is an integer from 0 to six;
  • n 1, 2 or 3;
  • the dotted line indicates the optional presence of a double bond; or a pharmaceutically acceptable salt thereof; provided that when the optional double bond is present there is no P 1 or R 10 and further provided that X is not oxygen in the definition of R 1 .
  • alkyl, alkenyl, alkynyl and alkoxy groups may be straight or branched.
  • halogen is used to mean iodo, fluoro, chloro or bromo.
  • Alkyl groups may be substituted by one or more halogens up to
  • R 9 and R 11 may be monovalent or divalent depending on their position in order to conform with the general laws of chemistry.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and diastereoisomers are contemplated to be within the scope of the present invention.
  • Preferred compounds are those wherein R 1 is X(CH 2 ) n Ar, (Ar is (a) or (b)), dihydrobenzofuranyl, benzodioxanyl, cyclohexyl, or C 1-4 alkyl; R 2 is (a), (b), C 1-4 alkyl, indolyl or hydrogen; R 3 and R 5 are
  • R 4 is hydrogen, OH, C 1-5 alkoxy, halogen, C 1-4 alkyl, N(R 6 ) 2 , NH(CO)CH 3 or S(O) p C 1-5 alkyl;
  • P 1 and P 2 are independently hydrogen, CO 2 H or tetrazole;
  • Ar is (a), (b), phenyl, or pyridyl; and
  • X is (CH 2 ) n or oxygen.
  • R 3 is hydrogen or -X(CH 2 ) n R 8 , R 11 CO 2 R 7 ; R 4 and R 5 are
  • a palladium (0) catalyst such as tetrakis (triphenylphosphine) palladium (0)
  • a solvent such as toluene/methanol
  • a base such as aqueous sodium carbonate
  • Aryl boronic acids of Formula (4) may be prepared by transmetallation of aryl halides of Formula (6):
  • Ar-Hal (6) wherein Hal is Cl, Br or I, with an alkyllithium, such as n-butyllithium in a solvent such as dry tetrahydrofuran at low temperature (-40°--78°C) followed by quenching with a trialkylborate, such as tri-isopropylborate, then treatment with an acid such as aqueous hydrochloric.
  • alkyllithium such as n-butyllithium in a solvent such as dry tetrahydrofuran at low temperature (-40°--78°C)
  • a trialkylborate such as tri-isopropylborate
  • R 2 -(CH 2 ) n -Hal (7) in a suitable solvent such as dimethylformamide or hexamethylphosphoramide in the presence of a suitable base such as sodium hydride affords compounds of Formula (8), n is not zero.
  • esters of Formula (8) Saponification of esters of Formula (8) with aqueous sodium hydroxide in a solvent such as ethanol or
  • compounds of Formula (5) may be obtained by coupling of compound of type (3) with an aryl stannane derivative of Formula (10):
  • Ar-SnX 3 (10) in the presence of a palladium (0) catalyst such as tetrakis (triphenylphosphine) palladium (0) in a solvent such as dioxan or dimethylformamide at approximately 100°C in the presence of anhydrous lithium chloride.
  • a palladium (0) catalyst such as tetrakis (triphenylphosphine) palladium (0) in a solvent such as dioxan or dimethylformamide at approximately 100°C in the presence of anhydrous lithium chloride.
  • Aryl stannanes of Formula (10) may be prepared by
  • n is not 0.
  • n is not zero, may be obtained by coupling of compound (12) with an aryl stannane derivative of Formula (10) in the presence of a palladium (0) catalyst such as
  • compounds of Formula (5) may be prepared by a process which comprises: alkylation of an ester of acetoacetic acid (13)
  • a suitable solvent such as acetonitrile and a base such as 1,8 diazabicyclo[5.4.0]undec-7-ene to afford compounds of Formula (15).
  • tetrahydrofuran may be used as the solvent and sodium hydride as the base for the alkylation.
  • pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sublingually, transdermally, rectally, via inhalation or via buccal administration.
  • compositions which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will be formulated as
  • composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose.
  • any routine encapsulation is suitable, for example using the
  • composition in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as
  • a typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • a binding and/or lubricating agent for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg, and preferably from 1 mg to 100 mg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person.
  • a topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I).
  • administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
  • Rat cerebellum or kidney cortex were rapidly dissected and frozen immediately in liquid nitrogen or used fresh.
  • the tissues 1-2 g for cerebellum or 3-5 g for kidney cortex, were homogenized in 15 mis of buffer containing 20mM Tris HC1 and 5mM EDTA, pH 7.5 at 4°C using a motor-driven homogenizer.
  • the homogenates were filtered through cheesecloth and centrifuged at 20,000 x g for 10 minutes at 4°C. The supernatant was removed and centrifuged at 40,000 xg for 30 minutes at 4°C.
  • the resulting pellet was resuspended in a small volume of buffer containing 50 mM Tris, 10 mM MgCl 2 , pH 7.5;
  • the membranes were diluted to give 1 and 5 mg of protein for each tube for cerebellum and kidney cortex in the binding assay.
  • Freshly isolated rat mesenteric artery and collateral vascular bed were washed in ice cold saline (on ice) and lymph nodes were removed from along the major vessel. Then, the tissue was homogenized using a polytron in buffer containing 20 mM Tris and 5mM EDTA, pH 7.5 at 4°C in 15 ml volume for ⁇ 6 gm of mesenteric artery bed. The homogenate was strained through cheesecloth and centrifuged at 2,000 xg for 10 min. at 4°C. The
  • MgCl 2 MgCl 2 , 0.05% BSA, pH 7.5 buffer in a total volume of 100 ml.
  • Membrane protein was added to tubes containing either buffer or indicated concentration of compounds.
  • [ 125 I]ET-1 (2200 Ci/mmol) was diluted in the same buffer containing BSA to give a final concentration of 0.2-0.5 nM ET-1. Total and nonspecific binding were measured in the absence and presence of 100 nM unlabelled ET-1.
  • Rat aorta are cleaned of connective tissue and adherent fat, and cut into ring segments approximately 3 to 4 mm in length.
  • Vascular rings are suspended in organ bath chambers (10 ml) containing Krebs-bicarbonate solution of the following composition (millimolar):
  • Tissue bath solutions are maintained at 37°C and aerated continuously with 95% 0 2 / 5% CO 2 . Resting tensions of aorta are maintained at 1 g and allowed to equilibrate for 2 hrs., during which time the bathing solution is changed every 15 to 20 min. Isometric tensions are recorded on Beckman R-611 dynographs with Grass FT03 force-displacement transducer. Cumulative concentration-response curves to ET-1 or other contractile agonists are constructed by the method of step-wise addition of the agonist. ET-1 concentrations are increased only after the previous concentration produces a steady-state contractile
  • ET-1 induced vascular contractions are expressed as a percentage of the response elicited by 60 mM KC1 for each individual tissue which is determined at the beginning of each experiment. Data are expressed as the mean ⁇ S.E.M. Dissociation constants (K b ) of
  • EXAMPLE 3 3-(3,4-MethylenedioxyphenylAl-(4-methoxybenzyl)indole-2- carboxylic acid.
  • the title compound was prepared by alkylation of methyl 3-(2- carboethoxymethoxy-4-methoxyphenyl) indole-2-carboxylate (100 mg, 0.27 mmol) with 6-chloropiperonyl chloride (55 mg, 0.27 mmol) followed by saponification using methods previously described in example 2a then crystallized from EtOAc as the bis (dicyclohexylamine) salt (97 mg, 41%);
  • the title compound was prepared by alkylation of ethyl 5- benzyloxy-3-(3,4-methylenedioxyphenyl)indole-2- carboxylate with 2-carboethoxymethoxy-4-methoxybenzyl chloride followed by saponification using methods
  • EXAMPLE 7 1-(2-Carhoxymethoxy-4-methoxvbenzyl)-3-(3,4- methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2-carboxylic acid. a) Ethyl 1-(2-carboethpxymethoxy-4-methoxybenzyl)-5- hvdroxy-3-(3,4-methylenedioxyphenyl)indole-2-carboxylate.
  • the title compound was prepared from ethyl 1-(2- carboethoxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2- carboxylate (50 mg, 0.085 mmol) by the method given in example 3d (33mg, 73%); m.p. 190 - 191° C.
  • the title compound was prepared from ethyl 1-(2-carboethoxymethoxy-4-methoxybenzyl)-5-hydroxy-3- (3,4-methylenedioxyphenyl) indole-2-carboxylate (150mg, 0.26 mmol) and ethyl bromoacetate (55 mg, 0.33 mmol) by the method given in example 7b (119 mg, 69%).
  • incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • a compound of formula I (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Step 1 Blend ingredients No. 1, No. 2, No. 3 and
  • Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its converion to wet granules.
  • Step 3 The wet mass is converted to granules by
  • Step 4 The wet granules are then dried in an oven at
  • Step 5 The dry granules are lubricated with
  • Step 6 The lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then steriled by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Abstract

Indole derivatives of formula (1) wherein the substituents are defined herein are disclosed. The compounds are useful in methods of antagonizing endothelin receptors, treating hypertension, treating renal failure and treating cerebrovascular disease. Pharmaceutical compositions are also disclosed.

Description

ENDOTHELIN RECEPTOR ANTAGONISTS
Field of the Invention The present invention relates to novel indole derivatives, pharmaceutical compositions containing these compounds and their use as endothelin receptor
antagonists. BACKGROUND
Endothelin (ET) is a highly potent
vasoconstrictor peptide synthesized and released by the vascular endothelium. Endothelin exists as three
isoforms, ET-1, ET-2 and ET-3. [Unless otherwise stated "endothelin" shall mean any or all of the isoforms of endothelin]. Endothelin has profound effects on the cardiovascular system, and in particular, the coronary, renal and cerebral circulation. Elevated or abnormal release of endothelin is associated with smooth muscle contraction which is involved in the pathogenesis of cardiovascular, cerebrovascular, respiratory and renal pathophysiology. Elevated levels of endothelin have been reported in plasma from patients with essential
hypertension, acute myocardial infarction, subarachnoid hemorrhage, atherosclerosis, and patients with uraemia undergoing dialysis.
In vivo, endothelin has pronounced effects on blood pressure and cardiac output. An intravenous bolus injection of ET (0.1 to 3 nmol/kg) in rats causes a transient, dose-related depressor response (lasting 0.5 to 2 minutes) followed by a sustained, dose-dependent rise in arterial blood pressure which can remain elevated for 2 to 3 hours following dosing. Doses above 3 nmol/kg in a rat often prove fatal.
Endothelin appears to produce a preferential effect in the renal vascular bed. It produces a marked, long-lasting decrease in renal blood flow, accompanied by a significant decrease in GFR, urine volume, urinary sodium and potassium excretion. Endothelin produces a sustained antinatriuretic effect, despite significant elevations in atrial natriuretic peptide. Endothelin also stimulates plasma renin activity. These findings suggest that ET is involved in the regulation of renal function and is involved in a variety of renal disorders including acute renal failure, cyclosporine
nephrotoxicity and chronic renal failure.
Studies have shown that in vivo, the cerebral vasculature is highly sensitive to both the vasodilator and vasoconstrictor effects of endothelin. Therefore, ET may be an important mediator of cerebral vasospasm, a frequent and often fatal consequence of subarachnoid hemorrhage.
ET also exhibits direct central nervous system effects such as severe apnea and ischemic lesions which suggests that ET may contribute to the development of cerebral infarcts and neuronal death.
ET has also been implicated in myocardial ischemia (Nichols et al. Br. J. Pharm. 99: 597-601, 1989 and Clozel and Clozel, Cire. Res., 65: 1193-1200, 1989) coronary vasospasm (Fukuda et al., Eur. J. Pharm. 165: 301-304, 1989 and Lϋscher, Circ. 83: 701, 1991) heart failure, proliferation of vascular smooth muscle cells, (Takagi, B-iochem & Biophys . Res. Commun.; 168: 537-543, 1990, Bobek et al ., Am. J. Physiol. 258.408-C415, 1990) and atherosclerosis, (Nakaki et al ., Biochem. & Biophys. Res. Commnn. 158: 880-881, 1989, and Lerman et al., New Eng. J. of Med. 325: 997-1001, 1991). Increased levels of endothelin have been shown after coronary balloon
angioplasty (Kadel et al., No. 2491 Circ. 82: 627, 1990).
Further, endothelin has been found to be a potent constrictor of isolated mammalian airway tissue including human bronchus (Uchida et al., Eur J. of Pharm. 154: 227-228 1988, LaGente, Clin. Exp. Allergy 20: 343- 348, 1990; and Springall et al ., Lancet, 337: 697-701,
1991).
Endothelin has been associated with the
induction of haemorrhagic and necrotic damage in the gastric mucosa (Whittle et al., Br. J. Pharm. 95: 1011- 1013, 1988); Raynaud's phenomenon, Cinniniello et. al., Lancet 337: 114-115, 1991); Migraine (Edmeads, Headache, Feb. 1991 p 127); Sepsis (Weitzberg et al., Circ. Shock 33: 222-227, 1991; Pittet et al., Ann. Surg. 213: 262- 264, 1991), Cyclosporin-induced renal failure or
hypertension (Eur. J . Pharmacol., 180: 191-192, 1990,
Kidney Int, 37: 1487-1491, 1990) and endotoxin shock and other endotoxin induced diseases (Biochem, Biophys, Res. Commun., 161: 1220-1227, 1989, Acta Physiol. Scand. 137: 317-318, 1989).
Thus, endothelin receptor antagonists would offer a unique approach toward the pharmacotherapy of hypertension, renal failure, cerebrovascular disease, myocardial ischemia, angina, heart failure, asthma, atherosclerosis, Raynaud's phenomenon, ulcers, sepsis, migraine, glaucoma, endotoxin shock, endotoxin induced multiple organ failure or disseminated intravascular coagulation, cyclosporin-induced renal failure and as an adjunct in angioplasty and prevention of restenosis. S U MMARY OF THE INVENTION
This invention comprises indole derivatives represented by Formula (I) and pharmaceutical
compositions containing these compounds, and their use as endothelin receptor antagonists which are useful in the treatment of a variety of cardiovascular and renal diseases including but not limited to: hypertension, acute and chronic renal failure, cyclosporine induced nephrotoxicity, stroke, cerebrovascular vasospasm, myocardial ischemia, angina, heart failure and
atherosclerosis.
This invention further constitutes a method for antagonizing endothelin receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I).
DETATLED DESCRIPTION OF THE INVENTION
The compounds of this invention are represented by structural Formula (I):
wherein:
Figure imgf000006_0001
R1 is -X(CH2)nAr or -X(CH2)nR8 or
Figure imgf000007_0001
(c) ;
R2 is hydrogen, Ar or (c) ;
P1 is -X (CH2) nR8 ;
P2 is -X (CH2 ) nR8 , or -XR9Y;
R3 and R5 are independently hydrogen, R11, OH, C1-8alkoxy, S(O)qR11, N(R6)2, Br, F, I, Cl, CF3, NHCOR6, -R11CO2R7, -XR9-Y, XY or -X(CH2)nR8 wherein the methylene groups of -X(CH2)nR8 may be unsubstituted or substituted by one or more -(CH2)nAr groups;
R4 is hydrogen, Ar, R11, OH, C1-5alkoxy,
S(O)qR11,N(R6)2, -X(R11), Br, F, I, Cl or NHCOR6 wherein the C1-5alkoxy may be unsubstituted or substituted by OH, methoxy or halogen;
R6 is independently hydrogen or C1-4alkyl;
R7 is independently hydrogen, C1-6alkyl or (CH2)nAr;
R8 is hydrogen, R11, CO2R7, CO2C(R7)2O(CO)XR7, -N(R7)SO2R7, PO3(R7)2; SO2NR7R11, CONR7SO2R11,
SO3R7SO2R7, SO3R7, SO2R7, P(O)(OR7)R7, CN, -C(O)N(R6)2, tetrazole or OR6;
R9 is C1-10alkyl, C2-10alkenyl or phenyl all of which may be unsubstituted or substituted by one or more OH, N(R6)2, COOH, halogen or XC1- 5alkyl;
R10 is R3 or R4;
R11 is C1-8alkyl, C2-8alkenyl, C2-8alkynyl all of which may be unsubstituted or substituted by one or more OH, CH2OH, N(R6)2 or halogen;
X is (CH2)n, O, NR6 or S(O)q;
Y is CH3 or -X(CH2)nAr;
Ar is:
Figure imgf000008_0001
naphthyl, indolyl, pyridyl, thienyl, oxazolidinyl, oxazolyl, thiazolyl, isothiazolyl,
pyrazolyl, triazolyl, tetrazolyl, imidazolyl,
imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, or pyrimidyl; all of which may be unsubstituted or substituted by one or more R3 or R4 groups;
A is C=O, or (C(R6)2)m;
B is -CH2- or -O-;
q is zero, one or two;
n is an integer from 0 to six;
m is 1, 2 or 3;
and the dotted line indicates the optional presence of a double bond; or a pharmaceutically acceptable salt thereof; provided that when the optional double bond is present there is no P1 or R10 and further provided that X is not oxygen in the definition of R1.
Also included in the invention are
pharmaceutically acceptable salt complexes.
All alkyl, alkenyl, alkynyl and alkoxy groups may be straight or branched. The term "halogen" is used to mean iodo, fluoro, chloro or bromo. Alkyl groups may be substituted by one or more halogens up to
perhalogenation. The substituents listed for R9 and R11 may be monovalent or divalent depending on their position in order to conform with the general laws of chemistry.
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and diastereoisomers are contemplated to be within the scope of the present invention. Preferred compounds are those wherein R1 is X(CH2)nAr, (Ar is (a) or (b)), dihydrobenzofuranyl, benzodioxanyl, cyclohexyl, or C1-4alkyl; R2 is (a), (b), C1-4alkyl, indolyl or hydrogen; R3 and R5 are
independently hydrogen, OH, C1-5alkoxy, halogen, -OC1- 4alkyl phenyl, R11CO2R7, C1-4alkyl, N(R6)2, NH(CO)CH3, - X(CH2)nR8, -XR9 pyridyl, phenyl or S(O)pC1-5alkyl; R4 is hydrogen, OH, C1-5alkoxy, halogen, C1-4alkyl, N(R6)2, NH(CO)CH3 or S(O)pC1-5alkyl; P1 and P2 are independently hydrogen, CO2H or tetrazole; Ar is (a), (b), phenyl, or pyridyl; and X is (CH2)n or oxygen.
More preferred are compounds wherein R3 is hydrogen or -X(CH2)nR8, R11CO2R7; R4 and R5 are
independently hydrogen, OH, C1-5alkoxy, SC1-5alkyl, F, Br, C1-3alkyl or NH2.
Most preferred are compounds wherein R1 is (b) and R2 is (a) or (b); A is CH2, B is -O-; there is an optional double bond; R3 is hydrogen, X(CH2)qCOOH or CH=CHCO2H, R4 is hydrogen, substituted phenyl, or C1- 2alkoxy; and R5, R10 and P2 are hydrogen.
Especially preferred are the following compounds:
1-(3 4-Methylenedioxybenzyl)-3-(4-methoxyphenyl)indole-2- carboxylic acid;
1-(2-Chloro-4,5-methylenedioxybenzyl)-3-(4- methoxyphenyl)indole-2-carboxylic acid; 3-(3,4-Methylenedioxyphenyl)-1-(4-methoxybenzyl)indole-2- carboxylic acid;
3-(2-Carboxymethoxy-4-methoxyphenyl)-1-(2-chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid; 5-Benzyloxy-1-(2-carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid;
1-(2-Carboxymethoxy-4-methoxybenzyl)-5-hydroxy-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid;
1-(2-Carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2-carboxylic acid;
5-Carboxymethoxy-1-(2-carboxymethoxy-4-methoxybenzyl)-3- (3,4-methylenedioxyphenyl)indole-2-carboxylic acid;
1-(2-Carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid;
4-[1-[2-Carboxy-3-(3,4-methylenedioxyphenyl)indolyl]]-4- (4-methoxyphenyl)butyric acid. The present invention provides compounds of Formula (1) above.
Figure imgf000010_0001
which can be prepared by a process which comprises: a) for compounds in which the optional double bond is present and there is no R10 or P1, reacting a compound of Formula (2),
Figure imgf000011_0001
wherein X is C1-5 alkyl, with bromine in a suitable solvent such as dimethylformamide to provide a
brompindole of Formula (3).
Figure imgf000011_0002
Coupling of Compound (3) with a boronic acid of formula (4):
R
Figure imgf000011_0004
in the presence of a palladium (0) catalyst, such as tetrakis (triphenylphosphine) palladium (0), in a solvent such as toluene/methanol in the presence of a base such as aqueous sodium carbonate, at approximately 100°C, provides an indole of Formula (5).
Figure imgf000011_0003
Aryl boronic acids of Formula (4) may be prepared by transmetallation of aryl halides of Formula (6):
Ar-Hal (6) wherein Hal is Cl, Br or I, with an alkyllithium, such as n-butyllithium in a solvent such as dry tetrahydrofuran at low temperature (-40°--78°C) followed by quenching with a trialkylborate, such as tri-isopropylborate, then treatment with an acid such as aqueous hydrochloric.
For compounds in which n is not 0, alkylation of an indole of Formula (5) with an halide of Formula (7):
R2-(CH2)n-Hal (7) in a suitable solvent such as dimethylformamide or hexamethylphosphoramide in the presence of a suitable base such as sodium hydride affords compounds of Formula (8), n is not zero.
Figure imgf000012_0001
Saponification of esters of Formula (8) with aqueous sodium hydroxide in a solvent such as ethanol or
isopropanol at reflux affords compounds of Formula (9), n is not zero.
Figure imgf000013_0001
Alternatively, compounds of Formula (5) may be obtained by coupling of compound of type (3) with an aryl stannane derivative of Formula (10):
Ar-SnX3 (10) in the presence of a palladium (0) catalyst such as tetrakis (triphenylphosphine) palladium (0) in a solvent such as dioxan or dimethylformamide at approximately 100°C in the presence of anhydrous lithium chloride. Aryl stannanes of Formula (10) may be prepared by
transmetallation of aryl halides of Formula (6) with an alkyllithium, such as n-butyllithium, in a solvent such as tetrahydrofuran at low temperature (-40°--78°C) followed by quenching with a trialkylchlorostannane of Formula (11).
Cl-SnX3 (11) b) As an alternative compounds of Formula (3) may be alkylated with an halide of Formula (7),n#0 in a suitable solvent such as dimethylformamide or
hexamethylphosphoramide in the presence of a suitable base such as sodium hydride to afford compounds of
Formula (12), n is not 0.
Figure imgf000014_0001
Coupling of Compound (12) with a boronic acid of formula (4) in the presence of a palladium (0) catalyst, such as tetrakis (triphenylphosphine) palladium (0), in a solvent such as toluene/methanol in the presence of a base such as aqueous sodium carbonate, at approximately 100°C, provides compounds of Formula (8) n is not zero.
As an alternative compounds of Formula (8) n is not zero, may be obtained by coupling of compound (12) with an aryl stannane derivative of Formula (10) in the presence of a palladium (0) catalyst such as
tetrakis (triphenylphosphine) palladium (0) in a solvent such as dioxan or dimethylformamide at approximately 100°C in the presence of anhydrous lithium chloride. c) As a further alternative, compounds of Formula (5) may be prepared by a process which comprises: alkylation of an ester of acetoacetic acid (13)
Figure imgf000014_0002
with a halide of Formula (14)
R1-CH2Hal (14) in a suitable solvent such as acetonitrile and a base such as 1,8 diazabicyclo[5.4.0]undec-7-ene to afford compounds of Formula (15). Alternatively tetrahydrofuran may be used as the solvent and sodium hydride as the base for the alkylation.
Figure imgf000015_0001
Treatment of a compound of type (15) with an aryl diazonium chloride of Formula (16)
Figure imgf000015_0002
in a suitable solvent such as ethyl acetate in the presence of a base such as aqueous sodium hydroxide solution affords, by Japp-Klingemann rearrangement, hydrazones of Formula (17).
Figure imgf000015_0003
Treatment of hydrazones of type (17) with a suitable acid such as gaseous hydrogen chloride in a solvent such as ethanol followed by reflux for a period from 0.5 to 12 hours affords indoles of Formula (5) . d) Compounds of type (1) where n is 0-6 may be prepared by a process which comprises: treatment of a compound of Formula (18)
Figure imgf000016_0001
with aqueous formaldehyde solution at reflux affords a product of Formula (19).
Figure imgf000016_0002
Treatment of compounds of type (19) with aqueous potassium cyanide at approximately 40°-50°C, affords nitriles of Formula (20).
Figure imgf000016_0003
Hydrolysis of a nitrile of type (20) with aqueous sodium hydroxide at reflux followed by acidification with an acid such as hydrochloric affords diacids of Formula (21).
Figure imgf000017_0001
Diesterification of compounds of type (21) is achieved by treatment with a suitable base such as 1,8
diazabicyclo[5.4.0]undec-7-ene in a solvent such as acetonitrile or dimethylformamide followed by addition of iodomethane to afford compounds of Formula (22).
Figure imgf000017_0002
Dieckmann cyclization of diesters of type (22) using a base such as sodium methoxide and methanol as solvent at reflux affords products of Formula (23).
Figure imgf000017_0003
Treatment of compounds of type (23) with
trifluoromethanesulfonic anhydride in pyridine as solvent affords triflates of Formula (24)
Figure imgf000018_0001
Compounds of Formula (8), X=Me, may be obtained by coupling of compound (24) with an aryl stannane
derivative of Formula (10) in the presence of a palladium
(0) catalyst such as
tetrakis (triphenylphosphine) palladium (0) in a solvent such as dioxan or dimethylformamide at approximately 100°C in the presence of anhydrous lithium chloride.
As an alternative compounds of Formula (8), X=Me, can be prepared by coupling of compound (24) with a boronic acid of formula (4) in the presence of a palladium (0)
catalyst, such as tetrakis (triphenylphosphine) palladium (0), in a solvent such as toluene/methanol in the
presence of a base such as aqueous sodium carbonate, at approximately 100°C. Saponification of compounds of Formula (8), X is Me, to provides indole-2-carboxylic acids of Formula (9) can be achieved by treatment with aqueous sodium hydroxide in a solvent such as ethanol or isopropanol at reflux. With appropriate manipulation and protection of any chemical functionalities, synthesis of the remaining compounds of the Formula (I) is accomplished by methods analogous to those above and to those described in the Experimental section.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Compounds of Formula (I) and their
pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sublingually, transdermally, rectally, via inhalation or via buccal administration.
Compounds of Formula (I) and their
pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will
generally consist of a suspension or solution of the compound or salt in a liquid carrier for example,
ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the
aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be
considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell. Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally
containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as
dichlorodifluoromethane or trichlorofluoromethane.
A typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.
Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg, and preferably from 1 mg to 100 mg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I). The daily dosage regimen for oral
administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by the following tests:
I. Binding Assay
A) Membrane Preparation
Rat cerebellum or kidney cortex were rapidly dissected and frozen immediately in liquid nitrogen or used fresh. The tissues, 1-2 g for cerebellum or 3-5 g for kidney cortex, were homogenized in 15 mis of buffer containing 20mM Tris HC1 and 5mM EDTA, pH 7.5 at 4°C using a motor-driven homogenizer. The homogenates were filtered through cheesecloth and centrifuged at 20,000 x g for 10 minutes at 4°C. The supernatant was removed and centrifuged at 40,000 xg for 30 minutes at 4°C. The resulting pellet was resuspended in a small volume of buffer containing 50 mM Tris, 10 mM MgCl2, pH 7.5;
aliquotted with small vials and frozen in liquid
nitrogen. The membranes were diluted to give 1 and 5 mg of protein for each tube for cerebellum and kidney cortex in the binding assay. Freshly isolated rat mesenteric artery and collateral vascular bed were washed in ice cold saline (on ice) and lymph nodes were removed from along the major vessel. Then, the tissue was homogenized using a polytron in buffer containing 20 mM Tris and 5mM EDTA, pH 7.5 at 4°C in 15 ml volume for ~6 gm of mesenteric artery bed. The homogenate was strained through cheesecloth and centrifuged at 2,000 xg for 10 min. at 4°C. The
supernatant was removed and centrifuged at 40,000 xg for 30 min. at 4°C. The resulting pellet was resuspended as explained above for cerebellum and kidney cortex.
Approximately 10 mg of membrane protein was used for each tube in binding experiments.
B) [125l]ET-1 Rinding Protocol
[125l]ET-1 binding to membranes from rat cerebellum (2-5 mg protein/assay tube) or kidney cortex (3-8 mg protein/assay tube) were measured after 60 minutes incubation at 30°C in 50 mM Tris HCl, 10 mM
MgCl2, 0.05% BSA, pH 7.5 buffer in a total volume of 100 ml. Membrane protein was added to tubes containing either buffer or indicated concentration of compounds.
[125I]ET-1 (2200 Ci/mmol) was diluted in the same buffer containing BSA to give a final concentration of 0.2-0.5 nM ET-1. Total and nonspecific binding were measured in the absence and presence of 100 nM unlabelled ET-1.
After the incubation, the reactions were stopped with 3.0 ml cold buffer containing 50 mM Tris and 10 mM MgCl2, pH 7.5. Membrane bound radioactivity was separated from free ligand by filtering through Whatman GF/C filter paper and washing the filters 5 times with 3 ml of cold buffer using a Brandel cell harvester. Filter papers were counted in a gamma counter with an efficiency of 75%. IC50's for the compounds of this invention range from 0.1 nm to 50 μm. II. ln Vitro Vascular Smooth Mnscle Activity
Rat aorta are cleaned of connective tissue and adherent fat, and cut into ring segments approximately 3 to 4 mm in length. Vascular rings are suspended in organ bath chambers (10 ml) containing Krebs-bicarbonate solution of the following composition (millimolar):
NaCl, 112.0; KCl, 4.7; KH2PO4, 1.2; MgSO4, 1.2; CaCl2, 2.5; NaHCθ3, 25.0; and dextrose, 11.0. Tissue bath solutions are maintained at 37°C and aerated continuously with 95% 02/ 5% CO2. Resting tensions of aorta are maintained at 1 g and allowed to equilibrate for 2 hrs., during which time the bathing solution is changed every 15 to 20 min. Isometric tensions are recorded on Beckman R-611 dynographs with Grass FT03 force-displacement transducer. Cumulative concentration-response curves to ET-1 or other contractile agonists are constructed by the method of step-wise addition of the agonist. ET-1 concentrations are increased only after the previous concentration produces a steady-state contractile
response. Only one concentration-response curve to ET-1 is generated in each tissue. ET receptor antagonists are added to paired tissues 30 min prior to the initiation of the concentration-response to contractile agonists.
ET-1 induced vascular contractions are expressed as a percentage of the response elicited by 60 mM KC1 for each individual tissue which is determined at the beginning of each experiment. Data are expressed as the mean ± S.E.M. Dissociation constants (Kb) of
competitive antagonists were determined by the standard method of Arunlakshana and Schild. The potency range for compounds of this invention range from 0.1 nM to 50 μm.
The following examples are illustrative and are not limiting of the compounds of this invention. EXAMPL E 1
1 - ( 3 , 4-Methylenedi oxybenzyl ) -3- (4-methoxyphenyl ) i ndole-2- carboxylic acid a) Ethyl 7-(4-methoxybenzyl)-3-oxobutyrate. To a stirred solution of ethyl acetoacetate (4.17 g, 31.9 mmol) and 4- methoxybenzyl chloride (5.0 g, 31.9 mmol) in CH3CN (25 mL) under an argon atmosphere was added 1,8- diazabicyclo[5.4.0]undec-7-ene (4.86 g, 31.9 mmol). After 3 h at room temperature, the mixture was partitioned between 3 N HCl (100 mL) and EtOAc (200 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried
(Na2SO4). The solvent was removed in vacuo to afford the title compound as an oil (6.65 g, 84%) which was used in the next step without further purification. b) Ethyl 3-(4-methoxyphenyl)indole-2-carboxylate. To a solution of ethyl 2-(4-methoxybenzyl)-3-oxobutyrate (1.0 g, 4 mmol) in EtOAc (6 mL) stirred at ice bath
temperature under an argon atmosphere was added a
solution of NaOH (0.48 g, 12 mmol) in H2O (2 mL). This was immediately followed by the addition of an aqueous solution of benzenediazonium chloride (4.2 mmol)
[prepared from aniline, (0.39 g, 4.2 mmol) in 6 N HC1
(0.5 mL) and NaNO2 (0.29 g, 4.2 mmol)]. After 10 min the mixture was partitioned between EtOAc (50 mL) and H2O (25 mL). The aqueous layer was washed with EtOAc (15 mL). The combined organic extracts were washed with saturated aqueous NaCl solution, dried (Na2SO4) and the solvent was removed in vacuo . The residue was dissolved in EtOH (10 mL) and the solution was saturated with HCl gas. This was refluxed for 1 h then cooled to room temperature and partitioned EtOAc (50 mL) and saturated aqueous NaHCO3 solution (50 mL). The aqueous layer was washed with EtOAc (15 mL). The combined organic extract was washed with H2O then saturated aqueous NaCl solution, dried (Na2SO4) and the solvent was removed in vacuo . Chromatography (silica gel, gradient elution from 25% Et2O / hexanes to 45% Et2O / hexanes) followed by crystallization from EtOAc / hexanes to afford the title compound (0.32 g, 27%); m.p. 109 - 111°C. c) Ethyl 1-(3,4-methylenedi oxybenzyl)-3-(4-methoxyphenyl)indole-2-carboxylate. To a solution of ethyl 3-(4- methoxyphenyl) indole-2-carboxylate (110 mg, 0.37 mmol) in HMPA (2 mL) stirred at ice bath temperature under an argon atmosphere was added NaH (14 mg of 80% oil
dispersion, 0.46 mmol, oil removed by pentane wash).
After 15 min a solution of piperonyl chloride (128 mg, 0.75 mmol) in HMPA (0.5 mL) was added and the ice bath removed. The reaction mixture was stirred 7 h at room temperature then partitioned between 3 N HCl (25 mL) and EtOAc (50 mL). The organic extract was washed
successively with H2O, aqueous NaHC03, H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo. The residue was purified by chromatography (silica gel, gradient elution from 25% Et2O / hexanes to 45% Et2O / hexanes) to afford the title compound (105 mg, 66%) d) 1-(3,4-Methylenedioxybenzyl)-3-(4-methoxyphenyl)- indole-2-carboxylic acid. A solution of ethyl 1-(3,4- methylenedioxybenzyl)-3-(4-methoxyphenyl) indole-2- carboxylate (35 mg, 0.08 mmol) in EtOH (10 mL) with aqueous 1 N NaOH (0.45 mL) was stirred under an argon atmosphere at room temperature for 17 h then refluxed for 3 h. The reaction mixture was cooled to room temperature then poured into H2O (20 mL) and the solvent volume was reduced to ca. 20 mL under reduced pressure. The aqueous solution was extracted with Et2O (15 mL) and the Et2O extract discarded. The aqueous layer was acidified with 6 N HCl and the product extracted into EtOAc. The organic extract was washed with H2O then saturated aqueous NaCl, dried (Na2SO4) and the solvent removed in vacuo .
Crystallization from EtOAc / hexanes afforded the title compound (21 mg, 66%); m.p. 205 - 206° C.
EXAMPLE 2
1-(2-Chloro-4,5-methylenedioxyhenzyl)-3-(4- methoxyphenyl)indole-2-carhoxylic acid a) 1-(2-Chloro-4,5-methylenedioxybenzyl)-3-(4- methoxyphenyl)indnle-2-carhnxylic acid. To a solution of ethyl 3- (4-methoxyphenyl) indole-2-carboxylate (365 mg, 1.24 mmol) in HMPA (3 mL) stirred at ice bath temperature under an argon atmosphere was added NaH (46.5 mg of 80% oil dispersion, 1.55 mmol, oil removed by pentane wash). After 15 min at ice bath temperature, a solution of 6- chloropiperonyl chloride (753 mg, 1.86 mmol) in HMPA (1 mL) was added and the ice bath removed. The reaction mixture was stirred 18 h at room temperature then partitioned between 3 N HCl (25 mL) and EtOAc (50 mL). The organic extract was washed successively with H2O, saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo and the residue (a mixture of acid and ethyl ester) was dissolved in EtOH (30 mL) and aqueous 2 N NaOH (2.5 mL) was added. This was then stirred under an argon atmosphere at reflux temperature for 3 h then cooled to room temperature and poured into H2O (50 mL). The solvent volume was reduced to ca. 45 mL under reduced pressure. The aqueous solution then
extracted with Et2O (20 mL) and the Et2O extract
discarded. The aqueous layer was acidified with 6 N HCl and the product extracted into EtOAc. The organic extract was washed with H2O then saturated aqueous NaCl and dried (Na2SO4). Removal of the solvent in vacuo yielded a yellow gum (497 mg). A portion (70 mg) was purified by reverse phase chromatography (CH3CN/ H2O = 55/ 45)
followed by crystallization from EtOAc/ hexanes to afford the title compound (50 mg); m.p. 204 - 205°C.
MS. : 453 [(M+NH4)+].
Anal. calc. for C24H18ClN05·¼ H2O : C, 65.46; H, 4.23; N, 3.18. Found C, 65.38; H, 4.00; N, 2.96.
EXAMPLE 3 3-(3,4-MethylenedioxyphenylAl-(4-methoxybenzyl)indole-2- carboxylic acid. a) Ethyl 3-bromoindole-2-carboxylate. To a solution of ethyl indole-2-carboxylate (25.0 g, 132 mmol) in DMF (50 mL), stirred at room temperature under an argon
atmosphere, was added dropwise a solution of Br2 (23.3g, 145 mmol) in DMF (80 mL). Upon completion of the
addition, the reaction mixture was stirred an additional 5 min then poured into ice water. The resulting solid was collected by filtration then crystallized from EtOAc/ hexanes to afford the title compound (29.9 g, 85%); m.p. 149 - 150° C. b) Ethyl 3-bromo-1-(4-methoxyhenzyl)indole-2- carboxylate. To a solution of ethyl 3-bromoindole-2- carboxylate (2.0 g, 7.46 mmol) and 4-methoxybenzyl chloride (7.46 mmol) in HMPA (5 mL) was added a slurry of NaH (240 mg of 80% oil dispersion, oil removed by pentane washing, 8.0 mmol) in HMPA (1 mL). After 30 min at room temperature the reaction mixture was partitioned between 3 N HCl (100 mL) and EtOAc (150 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O, saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to afford the title compound (2.55 g, 88%) which was used in the next step without further purification. C) 3,4-(Methylenedioxy)phenyltr ibutyltin. To a solution of 4-bromo-1,2-(methylenedioxy)benzene (5.0 g, 24.9 mmol) in THF (20 mL) at -78 ° C under an argon atmosphere was added butyllithium (11.4 mL of a 2.4 M solution in hexanes, 27.4 mmol). The mixture was warmed to 0° C over a 10 min period then treated with tributyltin chloride (6.8 mL, 25 mmol). After 1 h the mixture was partitioned between Et2O and H2O. The organic extract was washed with brine, dried (Na2SO4) and the solvent removed in vacuo. The resulting oil was purified by flash column
chromatography (silica gel, with hexanes as eluent) to afford the title compound (3.64g, 35%). d) Ethyl 1-(4-methnxybenzyl)-3-(3,4-methylene- dioxyphenyl)indole-2-carhnxy]ate. An anhydrous solution of ethyl 3-bromo-l- (4-methoxybenzyl) indole-2-carboxylate (388 mg, 1.0 mmol), LiCl (56 mg, 1.3 mmol), 3,4- (methylenedioxy)phenyltributyltin (1.24 g, 3.0 mmol) and tetrakis (triphenylphosphine) palladium (0) (116 mg, 0.10 mmol) in DMF (5 mL) was stirred under an atmosphere of argon at 110° C for 18 h. The reaction mixture was cooled to room temperature then partitioned between 3 N HCl (25 mL) and EtOAc (75 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried (Na2So4). The solvent was removed in vacuo to yield a dark oil (1.4 g).
Purification by chromatography (silica gel, eluting with 35% Et2O/ hexanes) followed by crystallization from Et2O/ hexanes afforded the title compound (270 mg, 65%). e) 3-(3,4-Methylenedioxyphenyl)-1-(4-methoxybenzyl)- indole-2-carboxylic acid. A solution of ethyl 1-(4- methoxybenzyl)-3-(3,4-methylenedioxyphenyl)indole-2- carboxylate (110 mg, 0.25 mmol) in EtOH (10 mL) and 1 N aqueous NaOH solution (2.5 mL) was refluxed for 3 h. The reaction mixture was cooled to room temperature then poured into H2O (25 mL). The solvent volume was reduced to ca. 25 mL under reduced pressure. The aqueous solution then extracted with Et2O (20 mL) and the Et2O layer discarded. The aqueous layer was acidified with 6 N HCl and the product extracted into EtOAc. The organic extract was washed with H2O then saturated aqueous NaCl and dried (Na2SO4). Removal of the solvent in vacuo yielded a white solid (91 mg). Crystallization from EtOAc/ hexanes afforded the title compound (74 mg, 67%); m.p. 155 - 157° C.
MS : 419.3 [(M+NH4)+].
Anal. calc . for C24H19NO5 · ¼ H2O : C, 71 . 01 ; H, 4 . 84 ; N, 3 . 45 . Found C, 71 .24 ; H, 4 . 83; N, 3 .28 .
EXAMPLE 4
3-(2-Carboxymethoxy-4-methoxyphenyl)-1-(2-chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid. a) 2-Carboethoxymethoxy-4-methoxybenzaldehyde. To a solution of 2-hydroxy-4-methoxybenzaldehyde (1.315 g, 8.64 mmol) in dry DMF (5 mL) stirred at ice bath
temperature under an argon atmosphere was added a slurry of NaH (300 mg of 80% oil dispersion, oil removed by pentane wash, 10 mmol) in dry DMF (2 mL). After 15 min, ethyl bromoacetate (2.84 g, 17 mmol) was added and the ice bath removed and stirring continued for an additional 30 min at room temperature. The reaction mixture was partitioned between 3 N HCl (100 mL) and EtOAc (150 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O, saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to yield an oil (2.55 g) which was crystallized from Et2θ/ hexanes to afford the title compound (1.77 g, 86%); m.p. 61 - 62°C. b) Cis and trans methyl 2-aceyl-3-(2-carboethoxy- methoxy-4-methoxyphenyl)acrylate. A solution consisting of 2-carboethoxymethoxy-4-methoxybenzaldehyde (17.58 g, 73.86 mmol), methyl acetoacetate (12 mL, 111 mmol), acetic acid (1.6 mL) and piperidine (0.5 mL) was refluxed in benzene for 1 h with azeotropic removal of H2O. The solution was cooled and all volatiles were removed in vacuo to afford the title compound (20.46 g) as an oil which was used without further purification. c) Methyl 2-(2-carboethoxymethoxy-4-methnxyphenyl)-3- oxobutyrate. To a solution of cis and trans methyl 2- acetyl-3-(2-carboethoxymethoxy-4-methoxyphenyl) acrylate
(6.25 g, 18.6 mmol) in pyridine (25 mL) stirred at ice bath temperature under an argon atmosphere was added dropwise a slurry of NaBH4 (704 mg, 18.6 mmol) in pyridine (10 mL). After 30 min the reaction was quenched by the cautious addition of EtOAc (200 mL) and 3N HCl (200 mL). The layers were separated and the aqueous solution was washed with EtOAc. The combined organic extract was washed successively with H2O, aqueous NaHCO3, H2O, saturated aqueous NaCl and dried (Na2SO4) and the solvent was removed in vacuo. Chromatography (silica gel eluting with 25% Et2O/ hexanes followed by crystallization from EtOAc/ hexanes afforded the title compound (4.66 g, 74%); m.p. 60 - 61°C. d) Methyl 3-(2-carboethoxymethoxy-4-methoxyphenyl)- indole-2-carboxylate. The title compound was prepared from methyl 2-(2-carboethoxymethoxy-4-methoxyphenyl)-3- oxobutyrate (2.22 g, 6.62 mmol) and phenyldiazonium chloride (0.93 g, 6.62 mmol) using methods previously described in example lb (yield = 507 mg, 25%). e) 3-(2-Carboxymethoxy-4-methoxyphenyl)-1-(2-chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid. The title compound was prepared by alkylation of methyl 3-(2- carboethoxymethoxy-4-methoxyphenyl) indole-2-carboxylate (100 mg, 0.27 mmol) with 6-chloropiperonyl chloride (55 mg, 0.27 mmol) followed by saponification using methods previously described in example 2a then crystallized from EtOAc as the bis (dicyclohexylamine) salt (97 mg, 41%);
m.p. 154 - 156°C.
MS : 510.2 [(M+H)+].
Anal. calc. for C26H20ClNO8·C24H46N2.½ H2O : C, 68.12; H, 7.66; N, 4.77. Found C, 68.07; H, 7.60; N, 4.75.
EXAMPLE 5
5-Benzyloxy-1-(2-carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid. a) 3,4-Methylenedioxyphenylboric acid. To a solution of 4-bromo-1,2-(methylenedioxy) benzene (10.05 g, 50 mmol) in dry THF (40 mL) stirred under an argon atmosphere at -78° C was added over a 3 min period BuLi (20 mL of a 2.5M solution in hexanes, 50 mmol) . After 15 min at -78° C this solution was added via cannula to a -78° C solution of triisopropyl borate (57 mL, 250 mmol) in THF (50 mL). The cooling bath was removed and stirring continued for 40 min.The reaction mixture was partitioned between 3 N HCl (200 mL) and EtOAc (250 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo and the resulting solid crystallized from EtOAc/ hexanes to afford the title compound (5.06 g, 61%); m.p. 247 - 252°C. b) Ethyl 5-benzyloxy-3-bromoindole-2-carboxylate. The title compound was prepared from ethyl 5-benzyloxyindole- 2-carboxylate (7.80 g, 26,4 mmol) by the method
previously described in example 3a (5.95 g, 60%); m.p. 147 - 148°C.
C) Ethyl 5-benzyloxy-3-(3,4-methylenedioxyphenyl)- indole-2-carboxylate. To a solution of ethyl 5-benzyloxy- 3-bromoindole-2-carboxylate (2.39 g, 6.39 mmol) and tetrakis (triphenylphosphine) -palladium (0) (250 mg, 0.22 mmol) in toluene (32 mL) was added 2 M aqueous solution of Na2CO3 (6.4 mL) and a solution of 3,4- (methylenedioxy)phenylboric acid (1.41 g, 8.5 mmol) in CH3OH (16 mL). This mixture was stirred at 90° C under an argon atmosphere for 1 h then partitioned between 3 N HCl (100 mL) and EtOAc (250 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo and the resulting solid crystallized from EtOH to afford the title compound (2.38 g, 90%);
m.p. 135 - 136°C. d) 2-Carboethoxymethoxy-4-methoxybenzyl alcohol. To a solution of 2-carboethoxymethoxy-4-methoxybenzaldehyde (15.50 g, 65.1 mmol) in EtOH (100 mL) and DMF (25 mL) stirred at ice bath temperature under an argon atmosphere was added portionwise NaBH4 (4.93 g, 130 mmol). The ice bath was removed and stirring continued for 15 min. The reaction was quenched by the cautious addition of EtOAc (200 mL) and 3 N HCl (200 mL) . The layers were separated and the organic extract was washed successively with H2O, aqueous NaHCO3, H2O, saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to afford the title compound (13.6 g, 87%) and was used without further purification. e) 2-Carboethoxymethoxy-4-methnxyhenzyl chloride. To a solution of 2-carboethoxymethoxy-4-methoxybenzyl alcohol
(1.30 g, 5.4 mmol) in Et2O (50 mL) stirred at ice bath temperature under an argon atmosphere was added
concentrated HCl (1.4 mL). After 15 min EtOAc (50 mL) was added and the aqueous layer removed. The organic extract was washed successively with H2O, aqueous NaHCO3, H2O, saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to afford the title compound (1.25 g, 90%) as a white solid. f) 5-Benzyloxy-1-(2-carboxymethoxy-4-methoxybenzyl)-3- (3,4-methylenedioxyphenyl)indole-2-carboxylic acid. The title compound was prepared by alkylation of ethyl 5- benzyloxy-3-(3,4-methylenedioxyphenyl)indole-2- carboxylate with 2-carboethoxymethoxy-4-methoxybenzyl chloride followed by saponification using methods
previously described in examples lc and Id; m.p. 182 - 190° C.
MS : 580.0 [(M - H)-].
Anal. calc. for C32H27NO9·¼ H2O : C, 66.95; H, 4.83; N,
2.44. Found C, 66.90; H, 4.79; N, 2.27. EXAMPLE 6
1-(2-Carboxymethoxy-4-methoxybenzyl)-5-hydroxy-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid. a) 1-(2-Carboxymethnxy-4-methnxybenzyl)-5-hydroxy-3-
(3,4-methylenedioxyphenyl)indole-2-carboxylic acid To a solution of 5-benzyloxy-1-(2-carboxymethoxy-4- methoxybenzyl)-3-(3,4-methylenedioxyphenyl) indole-2- carboxylic acid (120 mg, 0.21 mmol) in EtOH (30 mL) was added 10% palladium on activated carbon (12 mg). the resulting suspension was shaken in a Parr pressure reaction apparatus under 50 psi H2 for 3 h, then the reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and the residue crystallized from EtOAc/ hexanes to afford the title compound (79 mg, 77%); m.p. 184-186°C.
MS : 514.0 [(M+Na)+].
EXAMPLE 7 1-(2-Carhoxymethoxy-4-methoxvbenzyl)-3-(3,4- methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2-carboxylic acid. a) Ethyl 1-(2-carboethpxymethoxy-4-methoxybenzyl)-5- hvdroxy-3-(3,4-methylenedioxyphenyl)indole-2-carboxylate. The title compound was prepared from ethyl 5-benzyloxy-1- (2-carboethoxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylate (460 mg, 0.735 mmol) by the method given in example 6; m.p. 128 - 130°C. b) Ethyl 1-(2-Carboethoxymethoxy-4-methoxybenzyl)-3- (3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2- carboxylate. To a solution of ethyl 1-(2- carboethoxymethoxy-4-methoxybenzyl)-5-hydroxy-3- (3,4- methylenedioxyphenyl)indole-2-carboxylate (175 mg, 0.30 mmol) in DMF stirred at ice bath temperature under an argon atmosphere was added a slurry of NaH (11 mg of 80% oil dispersion, 0.36 mmol, oil removed by pentane wash) in DMF (1 mL). After 15 min at ice bath temperature, 1- iodopropane (0.255 g, 1.5 mmol) was added and the ice bath was removed. The reaction mixture was stirred an
additional 30 min at room temperature then partitioned between 3 N HCl (25 mL) and EtOAc (75 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo and the resulting solid crystallized from EtOH to afford the title compound (83 mg 47%); m.p. 89 - 91°C. c) 1-(2-Carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)-5-(prop-1-y]oxy)indole-2-carboxylic acid. The title compound was prepared from ethyl 1-(2- carboethoxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2- carboxylate (50 mg, 0.085 mmol) by the method given in example 3d (33mg, 73%); m.p. 190 - 191° C.
MS : 556.0 [(M+Na)+].
Anal. calc. for C29H27NO9·¼ H2O : C, 64.74; H, 5.15; N, 2.60. Found C, 64.76; H, 5.25; N, 2.50. EXAMPLE 8
5-Carboxymethoxy-1-(2-oarboxymethoxy-4-methoxybenzyl)-3-
(3,4-methylenedioxyphenyl)indole-2-carboxylic acid. a) Ethyl 5-carboethoxymethoxy-1-(2-carboethoxymethoxy-4- methoxybenzyl)-3-(3,4-methylenedioxyphenyl)indole-2- carboxylate. The title compound was prepared from ethyl 1-(2-carboethoxymethoxy-4-methoxybenzyl)-5-hydroxy-3- (3,4-methylenedioxyphenyl) indole-2-carboxylate (150mg, 0.26 mmol) and ethyl bromoacetate (55 mg, 0.33 mmol) by the method given in example 7b (119 mg, 69%). b) 5-Carboxymethoxy-1-(2-carboxymethoxy-4-methoxy- benzyl)-3-(3,4-methylenedioxyphenyl)indole-2-carboxylic acid. The title compound was prepared from ethyl 5- carboethoxymethoxy-1-(2-carboethoxymethoxy-4- methoxybenzyl)-3-(3,4-methylenedioxyphenyl)indole-2- carboxylate (100 mg, 0.16mmol) by the method given in example 3d (yield = 76 mg, 87%); m.p. 203 - 205° C. MS : 572 . 0 [ (M+Na) +] .
Anal. calc. for C28H23NO11·¼ H2O : C, 60.71; H, 4.28; N,
2.53. Found C, 60.45; H, 4.14; N, 2.50. EXAMPLE 9
1-(2-Carboxymethoxy-4-methoxyhenzy])-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid. a) Ethyl 3-bromoindole-1-(2-carboethoxymethoxy-4- methoxybenzy])-2-rarboxylate. Ethyl 3-bronoindole-2- carboxylate (900 mg, 3.33 mmol) was alkylated with 2- carboethoxymethoxy-4-methoxybenzyl chloride (1.11 g, 4.3 mmol) by the method given in example lc to afford the title compound (0.97 g, 60%). b) 1-(2-Carboxymethoxy-4-methoxyhenzy])-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid. The title compound was prepared by the coupling of ethyl 3- bromoindole-1-(2-carboethoxymethoxy-4-methoxybenzyl)-2- carboxylate (500 mg, 0.93 mmol) with 4- (methylenedioxy)phenylboric acid 290 mg, 1.74 mmol) by the method given in example 5b followed by saponification using the method given in example 3d (277mg, 63%); m.p. 195 - 196° C.
MS : 493.3 [(M+NH4)+].
Anal. calc. for C26H21NO8·¼ H2O : C, 65.07; H, 4.51; N,
2.92. Found C, 64.86; H, 4.49; N, 2.87.
EXAMPLE 10
4-[1-[2-Carboxy-3-(3,4-methylenedioxyphenyl)indo]yl]]-4- (4-methoxyphenyl)butyric acid. a) Methyl 3-(4-methoxybenzoyl)propionate. To a solution of 3-(4-methoxybenzoyl)propionic acid (2.08 g, 10 mmol) in CH3CN (50 mL) stirred at ice bath temperature under an argon atmosphere was added 1,8-diazabicyclo[5.4.0]-undec- 7-ene (1.9 mL, 12.5 mmol followed by CH3I (1.25 mL, 20 mmol). The ice bath was removed and stirring continued for 5 h. The mixture was then partitioned between 3 N HCl (50 mL) and EtOAc (75 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to afford the title compound (1.88 g, 85%) as a white solid. b) Methyl 3-hydroxy-4-(4-methoxyphenyl)butyrate. To a stirred solution of methyl 3-(4-methoxybenzoyl)propionate (1.88 g, 8.5 mmol) in CH3OH (50 mL) at ice bath
temperature under an argon atmosphere was added NaBH4 (190 mg, 5 mmol). The reaction mixture was stirred 1 h at ice bath temperature then quenched by the cautious addition of EtOAc (100 mL) and 3N HCl (50 mL). The layers were separated and the aqueous layer was washed with EtOAc. The combined organic extract was washed
successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to yield a white solid which was crystallized from Et2O/ hexanes to afford the title compound (1.59 g, 84%).
C) Methyl 3-chloro-4-(4-methoxyphenyl)butyrate. To a solution of methyl 3-hydroxy-4-(4-methoxyphenyl)butyrate (0.50 g, 2.32 mmol) with triethylamine (1.1 ml, 7.8 mmol) in CH2CI2 (5 mL) stirred at ice bath temperature under an argon atmosphere was added methanesulfonyl chloride (0.26 mL, 3.4 mmol). After 30 min at ice bath temperature, the reaction mixture partitioned between 3 N HCl (50 mL) and EtOAc (75 mL). The organic extract was washed
successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl then dried (Na2SO4). The solvent was removed in vacuo to afford the title compound (453 mg, 84%) as an oil which crystallized on standing; m.p. 48 - 49° C. d) Methyl 4-[1-(3-bromo-2-carboethoxyindolyl)]-4-(4- methoxyphenyl) butyrate. To a solution of ethyl 3- bromoindole-2-carboxylate (469 mg, 1.75 mmol) in dry DMF stirred at ice bath temperature under an argon atmosphere was added NaH (66 mg of 80% oil dispersion, 2.19 mmol, oil removed by pentane wash) and stirring continued for 15 min. To this was added a solution of methyl 3-chloro- 4-(4-methoxyphenyl) butyrate (453 mg, 1.87 mmol). The ice bath was removed and stirring continued for 17 h. The reaction mixture partitioned between 3 N HCl (50 mL) and EtOAc (75 mL). The organic extract was washed
successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl then dried (Na2SO4) and the solvent was removed in vacuo . purification by flash chromatography silica gel eluting with 35% Et2O/ hexanes) afforded the title compound (75 mg, 21%). e) Methyl 4-[1-[2-carboethoxy-3-(3,4-methylenedioxyphenyl)indolyl]]-4-(4-methoxyphenyl)butyrate. A mixture consisting of methyl 4-[1-(3-bromo-2-carboethoxy- indolyl)]-4-(4-methoxyphenyl)butyrate (70 mg, 0.15 mmol), tetrakis (triphenylphosphine) palladium (O) (10 mg 0.009 mmol), toluene (2 mL), 2 M aqueous Na2CO3 (0.15 mL) and a solution of 3,4-(methylenedioxy) phenylboric acid (50 mg, 0.3 mmol) in CH3OH (1 mL) was stirred at 90°C under an argon atmosphere for 17 h. The reaction mixture partitioned between 3 N HCl (15 mL) and EtOAc (25 mL). The organic extract was washed successively with H2O, aqueous NaHCO3, H2O and saturated aqueous NaCl then dried (Na2SO4). The solvent was removed in vacuo to yield a dark oil (115 mg). Purification by flash chromatography (silica gel gradient elution from 25%Et2O/ hexanes to 50%Et2O/ hexanes) afforded the title compound (46 mg, 61%). f) 4-[1-[2-Carboxy-3-(3,4-methylenedioxyphenyl)- indolyl]]-4-(4-methoxyphenyl) butyric acid. To a warmed solution of methyl 4-[1-[2-carboethxy-3-(3,4- methylenedioxyphenyl)indolyl]]-4-(4-methoxyphenyl)butyrate (45 mg, 0.087 mmol) in EtOH (2 mL) was added 1 N aqueous NaOH (2 mL). This solution was refluxed for 1.5 h then cooled to room temperature and diluted with H2O (10 mL). The mixture was concentrated under reduced pressure. The aqueous residue was extracted with Et2O, and the Et2O extracts were discarded. The aqueous phase was acidified with 6 N HCl and extracted several times with EtOAc. The combined EtOAc extracts were washed successively with H2O and saturated aqueous NaCl and dried (Na2SO4). The solvent was removed in vacuo to provide an oily residue which was crystallized from Et2O to afford the title compound (24 mg);. m.p. 204-205° C. MS : 474 [(M+H)+].
EXAMPLES 11-19 The following examples were prepared by the methods given above.
1-(2-Chloro-4,5-methylenedioxybenzyl)-3-[2-(3- hydroxypropoxy]-4-methoxyphenyl)indole-2-carboxylic acid mp 177-178° C. 1-(2-Chloro-4,5-methylenedioxybenzyl)-3-(2-hydroxymethyl- 4-methoxyphenyl)indole-2-carboxylic acid
mp 131-132° C. 3-(2-Carboxy-4-methoxyphenyl)-1-(2-Chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid
mp 259-261° C.
3-[2-(2-Carboxyethoxy)-4-methoxyphenyl]-1-(2-Chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid
mp 231-233° C.
3-(2-Carboxymethyl-4-methoxyphenyl)-1-(2-Chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid
mp 237-239° C.
3-[2-[(E)-2-Carboxyethenyl]-4-methoxyphenyl]-1-(2-Chloro- 4,5-methylenedioxybenzyl)indole-2-carboxylic acid
mp 285-287° C.
3-[2-(2-Carboxyethyl)-4-methoxyphenyl]-1-(2-Chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid
mp 229-230° C. 1-(4-Carboxynaphth-l-ylmethyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid
mp 130° C.
1-(2'-Carboxybiphen-4-ylmethyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid
mp 147° C.
EXAMPLE 20 Formulations for pharmaceutical use
incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
Inhalant Formulation
A compound of formula I, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
Tablets/Ingredients Per Tablet
1. Active ingredient 40 mg
(Cpd of Form. I)
2. Corn Starch 20 mg
3. Alginic acid 20 mg
4. Sodium alginate 20 mg 5. Mg stearate 1.3 mg
2.3 mg
Procedure for tablets:
Step 1 Blend ingredients No. 1, No. 2, No. 3 and
No. 4 in a suitable mixer/blender.
Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its converion to wet granules.
Step 3 The wet mass is converted to granules by
passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. Step 4 The wet granules are then dried in an oven at
140°F (60°C) until dry.
Step 5 The dry granules are lubricated with
ingredient No. 5.
Step 6 The lubricated granules are compressed on a suitable tablet press. Parentera 1 Formulation
A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then steriled by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Claims

CLAIMS :
1. A compound of the formula (I)
wherein:
Figure imgf000043_0001
R1 is -X(CH2)nAr or -X(CH2)nR8 or
Figure imgf000043_0002
R2 is hydrogen, Ar or (c);
P1 is -X(CH2)nR8;
P2 is -X(CH2)nR8, or -XR9Y;
R3 and R5 are independently hydrogen, R11, OH, C1- 8alkoxy, S(O)qR11, N(R6)2, Br, F, I, Cl, CF3, NHCOR6, -R11CO2R7, -XR9-Y, XY or -X(CH2)nR8 wherein the methylene groups of - X(CH2)nR8 may be unsubstituted or substituted by one or more - (CH2)nAr groups;
R4 is hydrogen, Ar, R11, OH, C1-5alkoxy,
S(O)qR11,N(R6)2, -X(R11), Br, F, I, Cl or NHCOR6 wherein the C1- 5alkoxy may be unsubstituted or substituted by OH, methoxy or halogen;
R6 is independently hydrogen or C1-4alkyl; R7 is independently hydrogen, C1-6alkyl or (CH2)nAr;
R8 is hydrogen, R11, CO2R7, CO2C (R7)2O (CO) XR7, - N(R7)SO2R7, PO3(R7)2; SO2NR7R11, CONR7SO2R11, SO3R7SO2R7, SO3R7, SO2R7, P(O) (OR7)R7, CN, -C(O)N(R6)2, tetrazole or OR6;
R9 is C1-10alkyl, C2-10alkenyl or phenyl all of which may be unsubstituted or substituted by one or more OH, N(R6)2, COOH, halogen or XC1-5alkyl;
R10 is R3 or R4;
R11 is C1-8alkyl, C2-8alkenyl, C2-8alkynyl all of which may be unsubstituted or substituted by one or more OH, CH2OH, N(R6)2 or halogen;
X is (CH2)n, O, NR6 or S (O)q;
Y is CH3 or X(CH2)nAr;
Ar is:
Figure imgf000044_0001
naphthyl, indolyl, pyridyl, thienyl, oxazolidinyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl,
tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl,
isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, or pyrimidyl; all of which may be
unsubstituted or substituted by one or more R3 or R4 groups;
A is C=O, or (C(R6)2)m;
B is -CH2- or -O-;
q is zero, one or two;
n is an integer from 0 to six;
m is 1, 2 or 3; and the dotted line indicates the optional presence of a double bond; or a pharmaceutically acceptable salt thereof; provided that when the optional double bond is present there is no P1 or R10 and further provided that X is not oxygen for R1.
2. A compound of Claim 1 wherein R1 is X(CH2)nAr, dihydrobenzofuranyl, benzodioxanyl, cyclohexyl, or C1-4alkyl and R is (a), (b) or pyridyl; R2 is (a), (b), C1-4alkyl, indolyl or hydrogen; R3 and R5 are independently hydrogen, OH, C1-5alkoxy, halogen, -OC1-4alkyl phenyl, R11CO2R7, C1-4alkyl, N(R6)2,
NH(CO)CH3, -X(CH2)nR8, phenyl or S (O)pC1-5alkyl; R4 is hydrogen, OH, C1-5alkoxy, halogen, C1-4alkyl, N(R6)2, NH(CO)CH3 or S(O)pC1- 5alkyl; P1 and P2 are independently hydrogen, CO2H or tetrazole; and X is (CH2)n or oxygen.
3. A compound of Claim 2 wherein R3 is hydrogen or -X(CH2)nR8, R11CO2R7; R4 and R5 are independently hydrogen, OH, C1-5alkoxy, SC1-5alkyl, F, Br, C1-3alkyl or NH2. 4. A compound of Claim 3 wherein R1 is (b) and
R2 is (a) or (b); A is CH2, B is -O-; there is an optional double bond; R3 is hydrogen, X(CH2)qCOOH or CH=CHCO2H, R4 is hydrogen, or C1-2alkoxy; and R5, R10 and P2 are hydrogen. 5. A compound of Claim 1 selected from the group consisting of:
1-(3,4-Methylenedioxybenzyl)-3-(4-methoxyphenyl)indole-2- carboxylic acid;
1-(2-Chloro-4,5-methylenedioxybenzyl)-3-(4-methoxyphenyl)indole- 2-carboxylic acid; 3-(3,4-Methylenedioxyphenyl)-1-(4-methoxybenzyl)indole-2- carboxylic acid;
3-(2-Carboxymethoxy-4-methoxyphenyl)-1-(2-chloro-4,5- methylenedioxybenzyl)indole-2-carboxylic acid;
5-Benzyloxy-1-(2-carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl) indole-2-carboxylic acid; 1-(2-Carboxymethoxy-4-methoxybenzyl)-5-hydroxy-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid;
1-(2-Carboxymethoxy-4-methoxybenzyl)-3-(3,
4- methylenedioxyphenyl)-5-(prop-1-yloxy)indole-2-carboxylic acid;
5-Carboxymethoxy-1-(2-carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid;
1-(2-Carboxymethoxy-4-methoxybenzyl)-3-(3,4- methylenedioxyphenyl)indole-2-carboxylic acid;
4-[1-[2-Carboxy-3-(3,4-methylenedioxyphenyl)indolyl]]-4-(4- methoxyphenyl)butyric acid.
6. A pharmaceutical composition comprising a sufficient amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
7. A method of antagonizing endothelin receptors which comprises administering to a subject in need thereof, an effective amount to antagonize endothelin receptors of a compound of Claim 1.
8. A method of treating hypertension which comprises administering to a subject in need thereof an effective amount of a compound of Claim 1.
9. A method of treating renal failure which comprises administering to a subject in need thereof, an
effective amount of a compound of Claim 1.
10. A method of treating cerebrovascular disease which comprises administering to a subject in need thereof, an effective amount of a compound of
Claim 1.
PCT/US1993/012435 1992-12-22 1993-12-21 Endothelin receptor antagonists WO1994014434A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU58735/94A AU5873594A (en) 1992-12-22 1993-12-21 Endothelin receptor antagonists
JP6515386A JPH08504826A (en) 1992-12-22 1993-12-21 Endothelin receptor antagonist
US08/464,613 US5686481A (en) 1993-12-21 1993-12-21 Endothelin receptor antagonists
EP94904877A EP0676959A4 (en) 1992-12-22 1993-12-21 Endothelin receptor antagonists.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99546692A 1992-12-22 1992-12-22
US07/995,466 1992-12-22

Publications (1)

Publication Number Publication Date
WO1994014434A1 true WO1994014434A1 (en) 1994-07-07

Family

ID=25541843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/012435 WO1994014434A1 (en) 1992-12-22 1993-12-21 Endothelin receptor antagonists

Country Status (7)

Country Link
EP (1) EP0676959A4 (en)
JP (1) JPH08504826A (en)
CN (1) CN1096513A (en)
AU (1) AU5873594A (en)
MX (1) MX9400071A (en)
WO (1) WO1994014434A1 (en)
ZA (1) ZA939516B (en)

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
EP0755934A1 (en) 1995-07-28 1997-01-29 MERCK PATENT GmbH Endothelin receptor antagonists
EP0758650A1 (en) * 1995-08-16 1997-02-19 MERCK PATENT GmbH Endothelin receptor antagonists
WO1997013758A1 (en) * 1995-10-09 1997-04-17 MERCK Patent Gesellschaft mit beschränkter Haftung Pyridazinones as endothelin-receptor antagonists
US5622971A (en) * 1994-08-19 1997-04-22 Abbott Laboratories Endothelin antagonists
FR2740773A1 (en) * 1995-11-08 1997-05-09 Roussel Uclaf NOVEL IMIDAZOLE DERIVATIVES, PREPARATION METHOD, INTERMEDIATE OBTAINED, MEDICAMENT APPLICATION, PHARMACEUTICAL COMPOSITIONS, AND NOVEL USE
FR2740774A1 (en) * 1995-11-08 1997-05-09 Roussel Uclaf NOVEL IMIDAZOLE N-BENZYLDIOXOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
WO1997019077A1 (en) * 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Endothelin receptor antagonists
EP0800389A1 (en) * 1994-12-13 1997-10-15 Smithkline Beecham Corporation Novel compounds
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
WO1997043260A1 (en) * 1996-05-09 1997-11-20 Pfizer Inc. Indole derivatives useful as endothelin receptor antagonists
US5731321A (en) * 1995-08-02 1998-03-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Endothelin receptor antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
EP1021181A1 (en) * 1996-03-28 2000-07-26 Smithkline Beecham Corporation Carboxylic acid indole inhibitors of chemokines
WO2000066554A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation 3,3-substituted indoline derivatives
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6180643B1 (en) 1996-11-19 2001-01-30 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6291507B1 (en) 1998-02-17 2001-09-18 Astrazeneca Uk Limited Chemical compounds
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
WO2002030895A1 (en) * 2000-10-10 2002-04-18 Smithkline Beecham Corporation SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6436929B1 (en) 1999-05-04 2002-08-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6441004B1 (en) 1997-08-07 2002-08-27 Zeneca Limited Monocyte chemoattractant protein-1 inhibitor compounds
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6525083B2 (en) 2000-07-25 2003-02-25 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2003028719A1 (en) * 2001-09-27 2003-04-10 Bayer Healthcare Ag Substituted 2,5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases
US6569888B1 (en) 1999-02-05 2003-05-27 Astrazeneca Ab Anti-inflammatory indole derivatives
US6613760B1 (en) 1999-02-05 2003-09-02 Astrazeneca Ab Indole derivatives and their use as MCP-1 receptor antagonists
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US6737435B1 (en) 1999-02-05 2004-05-18 Astrazeneca Ab Indole derivatives and their use as MCP-1 antagonist
US6833387B1 (en) 1999-02-05 2004-12-21 Astrazeneca Ab Chemical compounds
US6852726B2 (en) 2002-02-01 2005-02-08 Syntex Llc Substituted indoles as alpha-1 agonists
US6890948B1 (en) * 2000-06-30 2005-05-10 Cancer Research Technology Limited Use of indole-3-acetic acid derivatives in medicine
US6911465B1 (en) 1999-02-05 2005-06-28 Astrazeneca Ab Anti-inflammatory indole derivatives
US6984657B1 (en) 2000-01-13 2006-01-10 Astrazeneca Ab Indole derivatives as MCP-1 receptor antagonists
US7008950B1 (en) 1997-06-05 2006-03-07 Takeda Chemical Industries, Ltd. Benzofurans as suppressors of neurodegeneration
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
WO2007146838A3 (en) * 2006-06-09 2008-03-13 Icos Corp Substituted phenyl acetic acids as dp-2 antagonists
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7351730B2 (en) 2001-06-20 2008-04-01 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7557135B2 (en) 2005-05-27 2009-07-07 Wyeth Inhibitors of cytosolic phospholipase A2
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7605172B2 (en) 2004-08-23 2009-10-20 Wyeth Thiazolo-naphthyl acids
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP2013100331A (en) * 2006-12-22 2013-05-23 Merck Sharp & Dohme Corp 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
US8710081B2 (en) 2005-11-04 2014-04-29 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8841295B2 (en) 2005-11-04 2014-09-23 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2016297558B2 (en) * 2015-07-20 2021-03-25 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321074B (en) * 2011-06-07 2013-04-10 山东轻工业学院 Indole ring-substituted pyrazole hydrazide derivative and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822375A (en) * 1986-03-06 1989-04-18 L'oreal Dyeing compositions for keratinous fibres based on indole derivatives, and new compounds
US4924004A (en) * 1981-08-08 1990-05-08 Kali-Chemie Pharma Gmbh 1-phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
US5013732A (en) * 1984-08-06 1991-05-07 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2038925A1 (en) * 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
CA2043741C (en) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4924004A (en) * 1981-08-08 1990-05-08 Kali-Chemie Pharma Gmbh 1-phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
US5013732A (en) * 1984-08-06 1991-05-07 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
US4822375A (en) * 1986-03-06 1989-04-18 L'oreal Dyeing compositions for keratinous fibres based on indole derivatives, and new compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0676959A4 *

Cited By (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US5622971A (en) * 1994-08-19 1997-04-22 Abbott Laboratories Endothelin antagonists
US6462194B1 (en) 1994-08-19 2002-10-08 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6380241B1 (en) 1994-08-19 2002-04-30 Abbott Laboratories Treatment of diseases using endothelin antagonists
US5731434A (en) * 1994-08-19 1998-03-24 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
WO1996015125A1 (en) * 1994-11-14 1996-05-23 Warner-Lambert Company Nonpeptide endothelin antagonists
EP0800389A4 (en) * 1994-12-13 1998-04-29 Smithkline Beecham Corp Novel compounds
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
EP0800389A1 (en) * 1994-12-13 1997-10-15 Smithkline Beecham Corporation Novel compounds
EP0755934A1 (en) 1995-07-28 1997-01-29 MERCK PATENT GmbH Endothelin receptor antagonists
US5700807A (en) * 1995-07-28 1997-12-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Endothelin receptor antagonists
US5731321A (en) * 1995-08-02 1998-03-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Endothelin receptor antagonists
US5986103A (en) * 1995-08-11 1999-11-16 Hoechst Marion Roussel 2-alkyl-1H-imidazole-5-carboxylic acids
EP0758650A1 (en) * 1995-08-16 1997-02-19 MERCK PATENT GmbH Endothelin receptor antagonists
US5821256A (en) * 1995-08-16 1998-10-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Endothelin receptor antagonists
WO1997013758A1 (en) * 1995-10-09 1997-04-17 MERCK Patent Gesellschaft mit beschränkter Haftung Pyridazinones as endothelin-receptor antagonists
WO1997017339A1 (en) * 1995-11-08 1997-05-15 Hoechst Marion Roussel Novel imidazole n-benzyldioxol derivatives, method for preparing same, resulting intermediates, pharmaceutical compositions and use of said derivatives as endothelin antagonists
WO1997017340A1 (en) * 1995-11-08 1997-05-15 Hoechst Marion Roussel Novel imidazole derivatives, method for preparing same, resulting intermediates, pharmaceutical compositions and use of said derivatives as endothelin antagonists
FR2740774A1 (en) * 1995-11-08 1997-05-09 Roussel Uclaf NOVEL IMIDAZOLE N-BENZYLDIOXOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
FR2740773A1 (en) * 1995-11-08 1997-05-09 Roussel Uclaf NOVEL IMIDAZOLE DERIVATIVES, PREPARATION METHOD, INTERMEDIATE OBTAINED, MEDICAMENT APPLICATION, PHARMACEUTICAL COMPOSITIONS, AND NOVEL USE
US6143774A (en) * 1995-11-08 2000-11-07 Hoechst Marion Roussel Imidazole n-benzyldioxol derivatives, method for preparing same, resulting intermediates, pharmaceutical compositions and use of said derivatives as endothelin antagonists
WO1997019077A1 (en) * 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Endothelin receptor antagonists
EP1021181A4 (en) * 1996-03-28 2002-06-26 Smithkline Beecham Corp Carboxylic acid indole inhibitors of chemokines
EP1021181A1 (en) * 1996-03-28 2000-07-26 Smithkline Beecham Corporation Carboxylic acid indole inhibitors of chemokines
WO1997043260A1 (en) * 1996-05-09 1997-11-20 Pfizer Inc. Indole derivatives useful as endothelin receptor antagonists
US6136843A (en) * 1996-05-09 2000-10-24 Pfizer Inc Indole derivatives useful as endothelin receptor antagonists
EA001471B1 (en) * 1996-05-09 2001-04-23 Пфайзер Инк. Indole derivatives useful as endothelinreceptor antagonists
US6306852B1 (en) 1996-05-09 2001-10-23 Pfizer Inc. Indole derivatives useful as endothelin receptor antagonists
AP830A (en) * 1996-05-09 2000-05-03 Pfizer Indole derivatives useful in therapy.
CN1124262C (en) * 1996-05-09 2003-10-15 辉瑞大药厂 Indole derivatives useful as endothelin receptor antagonists
US6605634B2 (en) 1996-11-19 2003-08-12 Amgen, Inc. Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
US6180643B1 (en) 1996-11-19 2001-01-30 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6440973B1 (en) 1996-11-19 2002-08-27 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US7008950B1 (en) 1997-06-05 2006-03-07 Takeda Chemical Industries, Ltd. Benzofurans as suppressors of neurodegeneration
US6953809B2 (en) 1997-08-07 2005-10-11 Zeneca Limited Monocyte chemoattractant protein-1 inhibitor compounds
US6441004B1 (en) 1997-08-07 2002-08-27 Zeneca Limited Monocyte chemoattractant protein-1 inhibitor compounds
US6291507B1 (en) 1998-02-17 2001-09-18 Astrazeneca Uk Limited Chemical compounds
US6911465B1 (en) 1999-02-05 2005-06-28 Astrazeneca Ab Anti-inflammatory indole derivatives
US6833387B1 (en) 1999-02-05 2004-12-21 Astrazeneca Ab Chemical compounds
US6737435B1 (en) 1999-02-05 2004-05-18 Astrazeneca Ab Indole derivatives and their use as MCP-1 antagonist
US6613760B1 (en) 1999-02-05 2003-09-02 Astrazeneca Ab Indole derivatives and their use as MCP-1 receptor antagonists
US6569888B1 (en) 1999-02-05 2003-05-27 Astrazeneca Ab Anti-inflammatory indole derivatives
US6583145B1 (en) 1999-05-04 2003-06-24 Wyeth Thio-oxindole derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6436929B1 (en) 1999-05-04 2002-08-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6441019B2 (en) 1999-05-04 2002-08-27 Wyeth Cyclocarbamate and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6503939B2 (en) 1999-05-04 2003-01-07 Wyeth Combination regimens using 3,3-substituted indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6521657B2 (en) 1999-05-04 2003-02-18 Wyeth Thio-oxindole derivatives
US6982261B2 (en) 1999-05-04 2006-01-03 Wyeth Cyanopyrroles
US6544970B2 (en) 1999-05-04 2003-04-08 Wyeth Cyclic regimens utilizing indoline derivatives
WO2000066554A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation 3,3-substituted indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6562857B2 (en) 1999-05-04 2003-05-13 Wyeth Cyanopyrroles
US6566358B2 (en) 1999-05-04 2003-05-20 Wyeth Cyclocarbamate derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6946454B2 (en) 1999-05-04 2005-09-20 Wyeth Thio-oxindole derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6608068B2 (en) 1999-05-04 2003-08-19 Wyeth Indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6693103B2 (en) 1999-05-04 2004-02-17 Wyeth 1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators
US6713478B2 (en) 1999-05-04 2004-03-30 Wyeth Cyclocarbamate derivatives as progesterone receptor modulators
US7081457B2 (en) 1999-05-04 2006-07-25 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6759408B2 (en) 1999-05-04 2004-07-06 Wyeth Combination regimens using progesterone receptor modulators
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6794373B2 (en) 1999-05-04 2004-09-21 Wyeth Contraceptive methods using benzimidazolones
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6835744B2 (en) 1999-05-04 2004-12-28 Wyeth 3,3-substituted indoline derivatives
US6841568B2 (en) 1999-05-04 2005-01-11 Wyeth Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6984657B1 (en) 2000-01-13 2006-01-10 Astrazeneca Ab Indole derivatives as MCP-1 receptor antagonists
US6890948B1 (en) * 2000-06-30 2005-05-10 Cancer Research Technology Limited Use of indole-3-acetic acid derivatives in medicine
EP1305285A4 (en) * 2000-07-25 2005-08-03 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
EP1305285A1 (en) * 2000-07-25 2003-05-02 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6525083B2 (en) 2000-07-25 2003-02-25 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6787651B2 (en) 2000-10-10 2004-09-07 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-γ binding agents
WO2002030895A1 (en) * 2000-10-10 2002-04-18 Smithkline Beecham Corporation SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351730B2 (en) 2001-06-20 2008-04-01 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7368471B2 (en) 2001-06-20 2008-05-06 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7629377B2 (en) 2001-06-20 2009-12-08 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7045544B2 (en) 2001-09-27 2006-05-16 Bayer Healthcare Ag Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases
WO2003028719A1 (en) * 2001-09-27 2003-04-10 Bayer Healthcare Ag Substituted 2,5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7906548B2 (en) 2001-12-03 2011-03-15 Wyeth Llc Methods for the use of inhibitors of cytosolic phospholipase A2
US6852726B2 (en) 2002-02-01 2005-02-08 Syntex Llc Substituted indoles as alpha-1 agonists
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7674818B2 (en) 2002-12-10 2010-03-09 Wyeth Llc Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7566791B2 (en) 2002-12-10 2009-07-28 Wyeth Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7160918B2 (en) 2002-12-10 2007-01-09 Hassan Mahmoud Elokdah Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1)
US7459478B2 (en) 2002-12-10 2008-12-02 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7803835B2 (en) 2003-09-25 2010-09-28 Wyeth Llc Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
US7605172B2 (en) 2004-08-23 2009-10-20 Wyeth Thiazolo-naphthyl acids
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
US8283373B2 (en) 2005-05-27 2012-10-09 Pfizer Inc. Inhibitors of cytosolic phospholipase A2
US7557135B2 (en) 2005-05-27 2009-07-07 Wyeth Inhibitors of cytosolic phospholipase A2
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US8710081B2 (en) 2005-11-04 2014-04-29 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8841295B2 (en) 2005-11-04 2014-09-23 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
WO2007146838A3 (en) * 2006-06-09 2008-03-13 Icos Corp Substituted phenyl acetic acids as dp-2 antagonists
JP2013100331A (en) * 2006-12-22 2013-05-23 Merck Sharp & Dohme Corp 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
US8772495B2 (en) 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
AU2016297558B2 (en) * 2015-07-20 2021-03-25 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11274108B2 (en) 2015-07-20 2022-03-15 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
AU2021204116B2 (en) * 2015-07-20 2022-12-01 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

Also Published As

Publication number Publication date
CN1096513A (en) 1994-12-21
AU5873594A (en) 1994-07-19
EP0676959A4 (en) 1996-01-03
ZA939516B (en) 1994-06-06
MX9400071A (en) 1994-07-29
JPH08504826A (en) 1996-05-28
EP0676959A1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
EP0676959A1 (en) Endothelin receptor antagonists
EP0650484B1 (en) Endothelin receptor antagonists
US6075037A (en) Endothelin receptor antagonists
EP0699069B9 (en) Endothelin receptor antagonists
US5834469A (en) Endothelin receptor antagonists
US5686481A (en) Endothelin receptor antagonists
US5559105A (en) Endothelin receptor antagonists
US5817653A (en) Endothelin receptor antagonists
US5736564A (en) Endothelin receptor antagonists
EP0778833B1 (en) Endothelin receptor antagonists
US5929106A (en) Endothelin receptor antagonists
US6620826B2 (en) Endothelin receptor antagonists
EP0817782B1 (en) Phenyl derivatives useful as endothelin receptor antagonists
US5817683A (en) Endothelin receptor antagonists
US6017952A (en) Endothelin receptor antagonists
US5716985A (en) Endothelin receptor antagonists
US5929116A (en) Cyclopentene derivatives as endothelin receptor antagonists
EP0693051A1 (en) Cyclopentene derivatives as endothelin receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08464613

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1994904877

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994904877

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994904877

Country of ref document: EP